Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dynamic Allocation Trial in mCRPC
NCT02703623Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2016
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Abiraterone Acetate Tablets (I), apalutamide, cabazitaxel ginsenoside liposome injection, carboplatin, ipilimumab and 1 more in prostate cancer (PCa) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Survival at 4 years, Incidence of adverse events at 4 years and 2 more. Started May 2016; status: active, not recruiting.
02
Drugs
Abiraterone Acetate Tablets (I)apalutamidecabazitaxel ginsenoside liposome injectioncarboplatinipilimumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02703623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02703623.